Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A
Date
2014
Authors
Hatchwell, L.
Girkin, J.
Dun, M.D.
Morten, M.
Verrills, N.
Toop, H.D.
Morris, J.C.
Johnston, S.L.
Foster, P.S.
Collison, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Allergy and Clinical Immunology, 2014; 133(6):1720-1727
Statement of Responsibility
Luke Hatchwell, Jason Girkin, Matthew D. Dun, Matthew Morten, Nicole Verrills, Hamish D. Toop, e Jonathan C. Morris, Sebastian L. Johnston, Paul S. Foster, Adam Collison, Joerg Mattes
Conference Name
Abstract
Background: β-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in vitro. Objective: We sought to elucidate the molecular mechanisms by which b-agonists exert anti-inflammatory effects in allergendriven and rhinovirus 1B–exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2- methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirusinduced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signalregulated kinase 1 and active nuclear factor kB subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.